Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Mechanisms of androgen-refractory prostate cancer.

Debes JD, Tindall DJ.

N Engl J Med. 2004 Oct 7;351(15):1488-90. No abstract available.

PMID:
15470210
[PubMed - indexed for MEDLINE]
2.

Androgen receptor signaling in androgen-refractory prostate cancer.

Grossmann ME, Huang H, Tindall DJ.

J Natl Cancer Inst. 2001 Nov 21;93(22):1687-97. Review.

PMID:
11717329
[PubMed - indexed for MEDLINE]
Free Article
3.

Androgen receptor action in hormone-dependent and recurrent prostate cancer.

Agoulnik IU, Weigel NL.

J Cell Biochem. 2006 Oct 1;99(2):362-72. Review.

PMID:
16619264
[PubMed - indexed for MEDLINE]
4.

Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.

Koutsilieris M, Bogdanos J, Milathianakis C, Dimopoulos P, Dimopoulos T, Karamanolakis D, Halapas A, Tenta R, Katopodis H, Papageorgiou E, Pitulis N, Pissimissis N, Lembessis P, Sourla A.

Expert Opin Investig Drugs. 2006 Jul;15(7):795-804. Review.

PMID:
16787142
[PubMed - indexed for MEDLINE]
5.

The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor.

Edwards J, Bartlett JM.

BJU Int. 2005 Jun;95(9):1320-6. Review. No abstract available.

PMID:
15892825
[PubMed - indexed for MEDLINE]
6.

Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.

Vis AN, Schröder FH.

BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. Review.

PMID:
19558559
[PubMed - indexed for MEDLINE]
7.

Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.

Nguyen MM, Wang Z.

Minerva Urol Nefrol. 2008 Mar;60(1):15-29. Review.

PMID:
18427432
[PubMed - indexed for MEDLINE]
8.

Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.

Landriscina M, Bagalà C, Piscazzi A, Schinzari G, Quirino M, Fabiano A, Bianchetti S, Cassano A, Sica G, Barone C.

Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.

PMID:
19152342
[PubMed - indexed for MEDLINE]
9.

Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.

Fujimoto N, Miyamoto H, Mizokami A, Harada S, Nomura M, Ueta Y, Sasaguri T, Matsumoto T.

Cancer Invest. 2007 Feb;25(1):32-7.

PMID:
17364555
[PubMed - indexed for MEDLINE]
10.

[Mechanism of loss of androgen dependency in androgen-dependent tumor].

Sato N, Suzuki H, Shimazaki J.

Hum Cell. 1993 Sep;6(3):170-5. Japanese.

PMID:
8297812
[PubMed - indexed for MEDLINE]
11.

The role of androgens and the androgen receptor in prostate cancer.

Debes JD, Tindall DJ.

Cancer Lett. 2002 Dec 10;187(1-2):1-7. Review.

PMID:
12359344
[PubMed - indexed for MEDLINE]
12.

[Prostate cancer and apoptosis].

Mayora A, Arvelo F.

Invest Clin. 2011 Dec;52(4):376-96. Review. Spanish.

PMID:
22523847
[PubMed - indexed for MEDLINE]
13.

Molecular regulation of androgen action in prostate cancer.

Dehm SM, Tindall DJ.

J Cell Biochem. 2006 Oct 1;99(2):333-44. Review.

PMID:
16518832
[PubMed - indexed for MEDLINE]
14.

[Molecular mechanisms involved in hormone resistance of prostate cancer].

Cabrespine A, Guy L, Chollet P, Debiton E, Bay JO.

Bull Cancer. 2004 Oct;91(10):747-57. Review. French.

PMID:
15556875
[PubMed - indexed for MEDLINE]
15.

Androgen axis in prostate cancer.

Culig Z, Bartsch G.

J Cell Biochem. 2006 Oct 1;99(2):373-81. Review.

PMID:
16598769
[PubMed - indexed for MEDLINE]
16.

Pharmacological values of medicinal mushrooms for prostate cancer therapy: the case of Ganoderma lucidum.

Mahajna J, Dotan N, Zaidman BZ, Petrova RD, Wasser SP.

Nutr Cancer. 2009;61(1):16-26. doi: 10.1080/01635580802379323. Review.

PMID:
19116872
[PubMed - indexed for MEDLINE]
17.

Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy.

Nelius T, Klatte T, de Riese W, Filleur S.

Int Urol Nephrol. 2008;40(1):97-104. Epub 2007 Jun 30.

PMID:
17602304
[PubMed - indexed for MEDLINE]
18.

Hormone treatment for prostate cancer: current issues and future directions.

Ichikawa T, Suzuki H, Ueda T, Komiya A, Imamoto T, Kojima S.

Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:58-63.

PMID:
16273367
[PubMed - indexed for MEDLINE]
19.

[Combined treatment of metastatic hormone-resistant prostate cancer].

Kaprin AD, Gafanov RA, Al'bitskiĭ IA, Fastovets SV.

Vopr Onkol. 2009;55(4):477-9. Russian. No abstract available.

PMID:
19947375
[PubMed - indexed for MEDLINE]
20.

Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence.

Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung HJ, Mudryj M.

Cancer Res. 2007 Oct 1;67(19):9001-5.

PMID:
17909000
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk